Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2'-MOE-ASOs.

Shemesh CS, Yu RZ, Warren MS, Liu M, Jahic M, Nichols B, Post N, Lin S, Norris DA, Hurh E, Huang J, Watanabe T, Henry SP, Wang Y.

Mol Ther Nucleic Acids. 2017 Dec 15;9:34-47. doi: 10.1016/j.omtn.2017.08.012. Epub 2017 Aug 30.

2.
3.

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S.

Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21.

PMID:
27665230
4.

Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.

Yu RZ, Gunawan R, Post N, Zanardi T, Hall S, Burkey J, Kim TW, Graham MJ, Prakash TP, Seth PP, Swayze EE, Geary RS, Henry SP, Wang Y.

Nucleic Acid Ther. 2016 Dec;26(6):372-380. Epub 2016 Aug 8.

PMID:
27500733
5.

[Difference of Species Sensitivities for Aquatic Life Criteria in China and the USA].

Wang XN, Yan ZG, Yu RZ, Wang WH, Chen LH, Liu ZT.

Huan Jing Ke Xue. 2016 Aug 8;37(8):3216-3223. doi: 10.13277/j.hjkx.2016.08.050. Chinese.

PMID:
29964753
6.

Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys.

Shemesh CS, Yu RZ, Gaus HJ, Greenlee S, Post N, Schmidt K, Migawa MT, Seth PP, Zanardi TA, Prakash TP, Swayze EE, Henry SP, Wang Y.

Mol Ther Nucleic Acids. 2016 May 10;5:e319. doi: 10.1038/mtna.2016.31.

7.

Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.

Yu RZ, Graham MJ, Post N, Riney S, Zanardi T, Hall S, Burkey J, Shemesh CS, Prakash TP, Seth PP, Swayze EE, Geary RS, Wang Y, Henry S.

Mol Ther Nucleic Acids. 2016 May 3;5:e317. doi: 10.1038/mtna.2016.26.

8.

Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice.

Shemesh CS, Yu RZ, Gaus HJ, Seth PP, Swayze EE, Bennett FC, Geary RS, Henry SP, Wang Y.

Nucleic Acid Ther. 2016 Aug;26(4):223-35. doi: 10.1089/nat.2016.0607. Epub 2016 Mar 31.

PMID:
27031383
9.

Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.

Yu RZ, Warren MS, Watanabe T, Nichols B, Jahic M, Huang J, Burkey J, Geary RS, Henry SP, Wang Y.

Nucleic Acid Ther. 2016 Apr;26(2):111-7. doi: 10.1089/nat.2015.0588. Epub 2016 Mar 9.

PMID:
26959999
10.

No effect on QT intervals of mipomersen, a 2'-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects.

Yu RZ, Gunawan R, Li Z, Mittleman RS, Mahmood A, Grundy JS, Singleton W, Geary R, Wang Y.

Eur J Clin Pharmacol. 2016 Mar;72(3):267-75. doi: 10.1007/s00228-015-1992-y. Epub 2015 Dec 9.

PMID:
26645588
11.

Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2'-o-(2-methoxyethyl) modifications.

Yu RZ, Grundy JS, Henry SP, Kim TW, Norris DA, Burkey J, Wang Y, Vick A, Geary RS.

Mol Ther Nucleic Acids. 2015 Jan 20;4:e218. doi: 10.1038/mtna.2014.69.

12.

Local and systemic tolerability of a 2'O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey.

Fey RA, Templin MV, McDonald JD, Yu RZ, Hutt JA, Gigliotti AP, Henry SP, Reed MD.

Inhal Toxicol. 2014 Jul;26(8):452-63. doi: 10.3109/08958378.2014.907587. Epub 2014 Jun 16.

PMID:
24932560
13.

[Evaluation of the acute toxicity of pharmaceutical wastewater to luminescent bacteria].

Du LN, Yang F, Mu YF, Yu RZ, Zuo JE, Gao JF, Yu X, Teng LJ, Tang XY.

Huan Jing Ke Xue. 2014 Jan;35(1):286-91. Chinese.

PMID:
24720217
14.

Clinical pharmacokinetics of second generation antisense oligonucleotides.

Yu RZ, Grundy JS, Geary RS.

Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):169-82. doi: 10.1517/17425255.2013.737320. Epub 2012 Dec 12. Review.

PMID:
23231725
15.

Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2.

Zanardi TA, Han SC, Jeong EJ, Rime S, Yu RZ, Chakravarty K, Henry SP.

J Pharmacol Exp Ther. 2012 Nov;343(2):489-96. doi: 10.1124/jpet.112.197426. Epub 2012 Aug 22.

16.

Progress of environmental management and risk assessment of industrial chemicals in China.

Wang H, Yan ZG, Li H, Yang NY, Leung KM, Wang YZ, Yu RZ, Zhang L, Wang WH, Jiao CY, Liu ZT.

Environ Pollut. 2012 Jun;165:174-81. doi: 10.1016/j.envpol.2011.12.008. Epub 2012 Jan 12. Review.

PMID:
22244592
17.

In vitro metabolic stabilities and metabolism of 2'-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates.

Baek MS, Yu RZ, Gaus H, Grundy JS, Geary RS.

Oligonucleotides. 2010 Dec;20(6):309-16. doi: 10.1089/oli.2010.0252. Epub 2010 Nov 30.

PMID:
21117960
18.

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

Yu RZ, Geary RS, Flaim JD, Riley GC, Tribble DL, vanVliet AA, Wedel MK.

Clin Pharmacokinet. 2009;48(1):39-50. doi: 10.2165/0003088-200948010-00003.

PMID:
19071883
19.

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.

Yu RZ, Lemonidis KM, Graham MJ, Matson JE, Crooke RM, Tribble DL, Wedel MK, Levin AA, Geary RS.

Biochem Pharmacol. 2009 Mar 1;77(5):910-9. doi: 10.1016/j.bcp.2008.11.005. Epub 2008 Nov 14.

PMID:
19056355
20.
21.

Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.

Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS.

Drug Metab Dispos. 2007 Mar;35(3):460-8. Epub 2006 Dec 15.

22.

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM.

Circulation. 2006 Oct 17;114(16):1729-35. Epub 2006 Oct 9.

23.

[Conjugation and immunogenic evaluation of complete immunogen for the small molecular environmental pollutants 2,4-D].

Yu RZ, He M, Shi HC, Liu J, Guo JH, Wang N, Qian Y.

Huan Jing Ke Xue. 2006 Jan;27(1):146-50. Chinese.

PMID:
16599138
24.

[Determination of 2,4-D using disposable amperometric immunosensor].

Cai Q, Yu RZ, He M, She HC.

Huan Jing Ke Xue. 2005 Nov;26(6):169-72. Chinese.

PMID:
16447453
25.

A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.

McHutchison JG, Patel K, Pockros P, Nyberg L, Pianko S, Yu RZ, Dorr FA, Kwoh TJ.

J Hepatol. 2006 Jan;44(1):88-96. Epub 2005 Oct 25.

PMID:
16274834
26.

Development of an ion-pair reverse-phase liquid chromatographic/tandem mass spectrometry method for the determination of an 18-mer phosphorothioate oligonucleotide in mouse liver tissue.

Murphy AT, Brown-Augsburger P, Yu RZ, Geary RS, Thibodeaux S, Ackermann BL.

Eur J Mass Spectrom (Chichester). 2005;11(2):209-15.

PMID:
16046805
27.

Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits.

Henry SP, Denny KH, Templin MV, Yu RZ, Levin AA.

Birth Defects Res B Dev Reprod Toxicol. 2004 Dec;71(6):368-73.

PMID:
15617022
28.

Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice.

Henry SP, Denny KH, Templin MV, Yu RZ, Levin AA.

Birth Defects Res B Dev Reprod Toxicol. 2004 Dec;71(6):359-67.

PMID:
15617021
29.
30.

Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys.

Yu RZ, Geary RS, Monteith DK, Matson J, Truong L, Fitchett J, Levin AA.

J Pharm Sci. 2004 Jan;93(1):48-59.

PMID:
14648635
31.

Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.

Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA.

Drug Metab Dispos. 2003 Nov;31(11):1419-28.

32.
33.

Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.

Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, Tami JA, Dorr FA.

J Pharmacol Exp Ther. 2002 Dec;303(3):1334-43.

34.

Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs.

Raoof AA, Ramtoola Z, McKenna B, Yu RZ, Hardee G, Geary RS.

Eur J Pharm Sci. 2002 Nov;17(3):131-8.

PMID:
12393140
35.
36.

Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.

Geary RS, Yu RZ, Levin AA.

Curr Opin Investig Drugs. 2001 Apr;2(4):562-73.

PMID:
11566019
37.

Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.

Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, Kwoh TJ, Dorr FA, Ratain MJ.

Clin Cancer Res. 2001 May;7(5):1214-20.

38.

Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.

Yu RZ, Geary RS, Leeds JM, Watanabe T, Moore M, Fitchett J, Matson J, Burckin T, Templin MV, Levin AA.

J Pharm Sci. 2001 Feb;90(2):182-93.

PMID:
11169535
39.

Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.

Yu RZ, Zhang H, Geary RS, Graham M, Masarjian L, Lemonidis K, Crooke R, Dean NM, Levin AA.

J Pharmacol Exp Ther. 2001 Feb;296(2):388-95.

40.

Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes.

Yu RZ, Geary RS, Leeds JM, Watanabe T, Fitchett JR, Matson JE, Mehta R, Hardee GR, Templin MV, Huang K, Newman MS, Quinn Y, Uster P, Zhu G, Working PK, Horner M, Nelson J, Levin AA.

Pharm Res. 1999 Aug;16(8):1309-15.

PMID:
10468036
41.

[Relationship of corrected visual acuity and macular lesion in high myopia].

Guan ZS, Yu RZ, Hu ZK.

Yan Ke Xue Bao. 1986 Sep;2(3):181-7. Chinese. No abstract available.

PMID:
3506873

Supplemental Content

Support Center